Hormonal responses to the new potent GnRH antagonist Cetrorelix.

Klingmüller D, Schepke M, Enzweiler C, Bidlingmaier F

Acta endocrinologica1 Jan 1993Cited by 40 (Europe PMC)

PMID8447189DOI10.1530/acta.0.1280015PepBankPUB-08447189

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In normal men, serum LH decreased rapidly after cetrorelix.
In plain wordsIn normal men, serum LH decreased rapidly after cetrorelix.
Peptide
Cetrorelix
Outcome
DecreaseLH suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.25, 0.5, 1.0, 1.5 or 3.0 mg · single doseAs given in this study (human).
Source sentences
Summary
Serum levels of LH, FSH and testosterone decreased rapidly with a dose-related decline for testosterone of 25%, 24%, 41%, 53% and 72%, respectively, for testosterone within the first 8 h of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718901
02HumanNon-randomized trialEfficacy outcome
In normal men, serum FSH decreased rapidly after cetrorelix.
In plain wordsIn normal men, serum FSH decreased rapidly after cetrorelix.
Peptide
Cetrorelix
Outcome
DecreaseFSH suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.25, 0.5, 1.0, 1.5 or 3.0 mg · single doseAs given in this study (human).
Source sentences
Summary
Serum levels of LH, FSH and testosterone decreased rapidly with a dose-related decline for testosterone of 25%, 24%, 41%, 53% and 72%, respectively, for testosterone within the first 8 h of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718902
03HumanNon-randomized trialEfficacy outcome
In normal men, cetrorelix 0.25 mg reduced testosterone by 25% within the first 8 h.
In plain wordsIn normal men, cetrorelix 0.25 mg reduced testosterone by 25% within 8 h.
Peptide
Cetrorelix
Outcome
DecreaseTestosterone suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.25 mg · single doseAs given in this study (human).
Measurements
Testosterone decline
25%
0.25 mg dose group, within first 8 h
Source sentences
Summary
Serum levels of LH, FSH and testosterone decreased rapidly with a dose-related decline for testosterone of 25%, 24%, 41%, 53% and 72%, respectively, for testosterone within the first 8 h of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718903
04HumanNon-randomized trialEfficacy outcome
In normal men, cetrorelix 0.5 mg reduced testosterone by 24% within the first 8 h.
In plain wordsIn normal men, cetrorelix 0.5 mg reduced testosterone by 24% within 8 h.
Peptide
Cetrorelix
Outcome
DecreaseTestosterone suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.5 mg · single doseAs given in this study (human).
Measurements
Testosterone decline
24%
0.5 mg dose group, within first 8 h
Source sentences
Summary
Serum levels of LH, FSH and testosterone decreased rapidly with a dose-related decline for testosterone of 25%, 24%, 41%, 53% and 72%, respectively, for testosterone within the first 8 h of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718904
05HumanNon-randomized trialEfficacy outcome
In normal men, cetrorelix 1.0 mg reduced testosterone by 41% within the first 8 h.
In plain wordsIn normal men, cetrorelix 1.0 mg reduced testosterone by 41% within 8 h.
Peptide
Cetrorelix
Outcome
DecreaseTestosterone suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.0 mg · single doseAs given in this study (human).
Measurements
Testosterone decline
41%
1.0 mg dose group, within first 8 h
Source sentences
Summary
Serum levels of LH, FSH and testosterone decreased rapidly with a dose-related decline for testosterone of 25%, 24%, 41%, 53% and 72%, respectively, for testosterone within the first 8 h of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718905
06HumanNon-randomized trialEfficacy outcome
In normal men, cetrorelix 1.5 mg reduced testosterone by 53% within the first 8 h.
In plain wordsIn normal men, cetrorelix 1.5 mg reduced testosterone by 53% within 8 h.
Peptide
Cetrorelix
Outcome
DecreaseTestosterone suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.5 mg · single doseAs given in this study (human).
Measurements
Testosterone decline
53%
1.5 mg dose group, within first 8 h
Source sentences
Summary
Serum levels of LH, FSH and testosterone decreased rapidly with a dose-related decline for testosterone of 25%, 24%, 41%, 53% and 72%, respectively, for testosterone within the first 8 h of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718906
07HumanNon-randomized trialEfficacy outcome
In normal men, cetrorelix 3.0 mg reduced testosterone by 72% within the first 8 h.
In plain wordsIn normal men, cetrorelix 3.0 mg reduced testosterone by 72% within 8 h.
Peptide
Cetrorelix
Outcome
DecreaseTestosterone suppression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.0 mg · single doseAs given in this study (human).
Measurements
Testosterone decline
72%
3.0 mg dose group, within first 8 h
Source sentences
Summary
Serum levels of LH, FSH and testosterone decreased rapidly with a dose-related decline for testosterone of 25%, 24%, 41%, 53% and 72%, respectively, for testosterone within the first 8 h of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718907
08HumanNon-randomized trialOther
In normal men, the hormonal effects of cetrorelix were reversible.
In plain wordsIn normal men, the hormonal effects of cetrorelix were reversible.
Peptide
Cetrorelix
Outcome
Not applicableReversibility
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.25, 0.5, 1.0, 1.5 or 3.0 mg · single doseAs given in this study (human).
Source sentences
Summary
All effects were reversible and no serious side effects were observed.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718908
09HumanNon-randomized trialSafety outcome
In normal men, no serious side effects were observed after cetrorelix.
In plain wordsIn normal men, no serious side effects were observed after cetrorelix.
Peptide
Cetrorelix
Outcome
Not applicableSerious side effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.25, 0.5, 1.0, 1.5 or 3.0 mg · single doseAs given in this study (human).
Source sentences
Summary
All effects were reversible and no serious side effects were observed.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718909
10HumanNon-randomized trialEfficacy outcome
In normal men given cetrorelix 3 mg, an early-morning LH peak occurred during suppression, coinciding with untreated men's testosterone peak.
In plain wordsIn men given cetrorelix 3 mg, an early-morning LH peak coincided with untreated men's testosterone peak.
Peptide
Cetrorelix
Outcome
Not applicableEarly-morning LH peak
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3 mg · single doseAs given in this study (human).
Source sentences
Summary
During the time of suppression after a dose of 3 mg there was an LH and testosterone peak in the early morning coinciding with the testosterone peak in untreated men.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718910
11HumanNon-randomized trialEfficacy outcome
In normal men given cetrorelix 3 mg, an early-morning testosterone peak coincided with the peak in untreated men.
In plain wordsIn men given cetrorelix 3 mg, an early-morning testosterone peak coincided with the peak in untreated men.
Peptide
Cetrorelix
Outcome
Not applicableEarly-morning testosterone peak
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3 mg · single doseAs given in this study (human).
Source sentences
Summary
During the time of suppression after a dose of 3 mg there was an LH and testosterone peak in the early morning coinciding with the testosterone peak in untreated men.
3 context sentences(design, population, supporting numbers)
Summary · context
We report here on a single-dose study with the new GnRH antagonist Cetrorelix (Ac-D-Nal(2)1, D-Phe(4C1)2, D-Pal3, D-Cit6, D-Alal0) in 25 normal men.
Summary · context
The study involved five different dose groups (0.25, 0.5, 1.0, 1.5 or 3.0 mg) and subjects were observed over a 40 h period.
Summary · context
Five men served as controls.
Report a problemFND-0844718911

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.